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Cardiovascular disease (CVD) was responsible for over 840,000 deaths in the United 
States in 2016 and costs an estimated $352 billion annually in both direct and indirect costs. 
Approximately every 40 seconds, an American will have an acute myocardial infarction (AMI), 
and at a similar rate an American will have a stroke. In patients who experienced AMI from 
2010 to 2016, statin use at hospital discharge increased from 92% to 99%. Nonetheless, 
cardiovascular disease remains the leading cause of death in the United States and more than 
one million coronary events are expected to occur in individuals in 2019; approximately 
335,000 of those cases will be recurrent coronary events. 1 Understanding the risk factors for 
CVD and then reducing those risks have the potential to decrease the impact of this disease.  
Of the multiple risk factors for CVD, dyslipidemia ranks high. The essence of this “lipid 
hypothesis” generated decades ago was the assumption of a positive relationship between low-
density lipoprotein cholesterol and the incidence of coronary disease. Although, significant 
evidence supporting elevated cholesterol as a primary risk factor for cardiovascular disease and 
major cardiovascular events was found, critics of the hypothesis believed that the postulation 
of causality was incompletely supported by those findings. 2 Accordingly, lowering low-density 
lipoprotein cholesterol with an HMG-CoA reductase inhibitor might provide incomplete 
protection from cardiovascular disease as is possibly evidenced by the residual risk a patient 
may have despite statin therapy. 
The first HMG-CoA reductase inhibitor was discovered in 1978 and became 
commercially available in 1987 when the US FDA advisory panel voted unanimously for 
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approval of the medication after clinical trials demonstrated its ability to significantly reduce 
plasma cholesterol compared with dietary modifications and other available medications such 
as bile acid sequestrants, fibrates, and nicotinic acid. Subsequent studies and trials with HMG-
CoA reductase inhibitors (aka, statins) further demonstrated substantial risk reduction for 
cardiovascular events such as myocardial infarction and stroke without any increase in non-
cardiovascular mortality.3 Statins have since revolutionized the treatment of hyper-
cholesterolemia and are the agents of choice for treatment and prevention of atherosclerotic 
cardiovascular disease. Indications for prescribing statins have broadened over time with the 
implementation of the American College of Cardiology (ACC) risk stratification calculator that 
gauges the risk of atherosclerotic cardiovascular disease (ASCVD) based on lipid levels and 
other risk factors. The ACC partnered with the American Heart Association (AHA) and created 
guidelines that stratified risk levels, and then specified the intensity of statin therapy according 
to the degree of risk. However, despite using these guidelines and the significant reduction in 
cardiovascular events attributed to the lipid lowering effects of statins, many patients still had 
residual risk for CVD.  
Hence, other means of reducing harmful lipids were researched. Nevertheless, statins 
were proven extremely efficacious. For this reason, instead of simply substituting statins with 
another agent, add-on therapy for lipid reduction was also explored along with investigating 
effects produced solely by other agents. Omega-3-fatty acid supplements, eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), were examined for lipid-lowering effects. Indeed, 
both EPA and DHA decreased both triglycerides (TG) and non-high-density lipoproteins (non-
HDL) and thereby, could possibly reduce the CVD risks and events. 
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EVOLVE II was a randomized controlled trial (RCT) that investigated the efficacy and 
safety of Epanova®, a lipid-regulating agent containing omega-3 carboxylic acid, which is a 
mixture of both EPA and DHA. An intermediate dose of Epanova® compared with olive oil 
significantly lowered TG and non-HDL levels in patients with severe hypertriglyceridemia 
(SHTG). Based on these findings, a clinical benefit from this agent for prevention of CVD risk and 
events was proposed.4 
The ROMANTIC trial was another randomized controlled trial that examined the safety 
and efficacy of adding omega-3 fatty acids (FAs) to statin therapy in patients with persistent 
elevations in TG despite statin therapy. This multicenter, double-blind, parallel group, placebo-
controlled study was just an eight-week trial that showed reductions in TG and non-HDL.5  
Both EVOLVE II and ROMANTIC were limited by small sample sizes (162 and 201 
participants, respectively), restricted generalizability (only Caucasians and middle-aged Asians, 
respectively, were studied) and short durations (12 weeks and 8 weeks, respectively). 
Nonetheless, these trials revealed significant improvements in TG and non-HDL levels, resulting 
from EPA and DHA combination therapy. By virtue of the lipid hypothesis, the evidence from 
these studies could be extrapolated to mean that omega-3 FAs may reduce CVD events, but 
these studies were not designed to measure this outcome. 
A murine study, however, did test the effect of omega-3 FAs on CVD, but without 
examining lipid levels. In 2015 Madingou et al. used 115 male Sprague-Dawley mice, to 
investigate the impact of EPA and DHA alone and in combination on induced myocardial infarct 
size. The mice experienced diminished infarct size with both EPA and DHA individually, but did 
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not obtain the same cardio-protection with the combination of EPA and DHA.6 Researchers 
speculated that this disparity might be due competition for like receptors. Alternatively, instead 
of receptor competition, the achievement of cardio-protection could have been mediated by 
increased protein kinase B (Akt) activity (with EPA and DHA alone) and decreased caspace-3 
activity (with DHA only). Although the results from this study cannot be applied directly to 
humans, the findings did suggest a mechanism whereby omega-3-FAs could be cardio-
protective. 
Other researchers have explored the specific relationships between EPA or DHA and 
cardiovascular disease. A study in Japan by Nishizaki et al. examined patients’ levels of EPA, 
DHA, and arachidonic acid (AA) in relation to a diagnosis of acute coronary syndrome (ACS). 
Patients with the lowest EPA/AA ratio had a greater probability of experiencing ACS compared 
with patients with the lowest DHA/AA ratio.7 A similar analysis by Iwamatsu et al. found that 
the found that the EPA/AA ratio, which was low, was more closely associated with ACS than the 
DHA/AA ratio.8  
Trials such as ROMANTIC or EVOLVE II have suggested that supplementation with 
polyunsaturated fatty acids (PUFAs), specifically omega-3-fatty acids, may confer cardiovascular 
benefits via reducing harmful lipids. However direct evidence establishing that EPA therapy 
lowers CVD events is lacking. Nonetheless, studies linking low EPA levels with an increased risk 
of ACS suggest a role for EPA supplementation in patients with residual CVD despite optimized 
statin therapy. Thus, whether adding EPA to statin therapy reduces CVD events in addition to 




In a retrospective cohort-based analysis including more than 11,000 patients, after 
adjustments for patient characteristics and concurrent medical therapy including statin use, 
Greene et al. found that omega-3 fatty acid treatment was independently associated with 
decreased risk of cardiovascular events in individuals after experiencing acute myocardial 
infarction.9 In a subsequent prospective, open-label, blind end point randomized trial, Nosaka 
et al. determined that early initiation of EPA combined with a statin in patients treated with 
successful primary PCI (percutaneous coronary intervention) after ACS reduced subsequent 
cardiovascular events.10 This study was the first to specifically assess the additive effect of EPA 
with a statin on cardiovascular events including death, nonfatal myocardial infarction, nonfatal 
stroke, and occurrence of new lesions requiring PCI or CABG. The trial also investigated the 
incidence of hospitalization for heart failure in those who received EPA and statin combination 
therapy compared to statin monotherapy. Absolute risk reduction was calculated at 11.0% and 
EPA/AA ratios were notably increased within a few days of initiating EPA at a dose of 1800 
mg/day. Though outcomes were assessed at 3-month intervals for only one year, the possible 
anti-inflammatory and anti-arrhythmic effects of EPA in the early phase after acute coronary 
syndrome may have contributed to both short- and long-term benefits and outcomes for 
patients.  
The posited anti-inflammatory effects of EPA from the above trial were consistent with 
results from a previous open-label study using surrogate endpoints in a small sample of at-risk 
patients. In that study, Nishio et al. assessed the impact of EPA and statin therapy compared to 
statin monotherapy on the stabilization of vulnerable plaques in patients with untreated 
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dyslipidemia and vulnerable plaques identified by thin cap fibroatheroma detected by 
multivessel optical coherence tomography (OCT). No significant difference in levels of low-
density lipoprotein or cardiovascular events were found between the two groups of 15 patients 
each. Nonetheless, after nine months, the EPA group had a greater increase in fibrous-cap 
thickness and a greater decrease in lipid length and arc, findings indicative of increased plaque 
stability. Researchers also noted decreased pentraxin-3 levels as well as decreased macrophage 
accumulation in the EPA and statin group both findings indicative of reduced inflammation.11 
These results suggested a benefit secondary to suppression of arterial inflammation, and 
researchers believed this mechanism would contribute to greater stabilization of unstable 
plaques and ultimately lead to decreased cardiovascular events. When linked to subsequent 
research, this mechanism provides a potential means to reduce cardiovascular risk that statins 
alone do not achieve. 
Niki et al. further explored the effect of EPA on coronary plaque components and local 
inflammatory cytokines after adding purified EPA ester to the existing treatment regimens of 
patients with dyslipidemia. Their blocked-randomization, open-label, single-center study 
provided evidence that the addition of EPA to strong statins was associated with a reduction in 
the lipid content of plaques in coronary arteries as observed by integrated backscatter 
intravascular ultrasound. Although some inherent limitations to IB-IVUS and the sample size of 
59 patients are limitations, a significant reduction in lipid volume and a significant increase in 
fibrous volume were only noted in the group receiving EPA in addition to a statin. Similarly, 
inflammatory cytokines, pentraxin-3 and monocyte chemoattractant protein-1 were not 
different in the group receiving statin monotherapy, but decreased in those receiving EPA.12  
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A more recent study by Watanabe et al. examined the effects of combination therapy 
with EPA and pitavastatin (PTV) compared with PTV alone on coronary plaque regression and 
stabilization as measured by integrated backscatter intravascular ultrasonography (CHERRY). 
This prospective, randomized, non-blinded, parallel, multicenter study which studied 193 
patients with coronary heart disease following PCI, and which had greater power than previous 
related studies, produced evidence that EPA and statin combination therapy achieved 
significant lipid volume reduction as well as significant reduction in total atheroma volume 
compared to statin monotherapy.13 Moreover, researchers noted no significant difference in 
the incidence of adverse events between the two groups including undesired elevation of low-
density lipoprotein cholesterol. These results were congruent with previous reports detailing 
the anti-inflammatory and anti-oxidative effects conferred by EPA therapy and suggested that 
EPA was safe and efficacious for reducing residual cardiovascular risks that existed despite 
optimized statin therapy.  
Conclusion 
Statins remain the pharmacologic agents of choice for reducing the risk of 
atherosclerotic cardiovascular disease. Despite treatment with high intensity statins, many 
patients have residual risk of CVD. Omega-3 fatty acids have been identified as a potential 
means to address this residual risk and do so via mechanisms different from those of HMG-CoA 
reductase agents. Although research specifically supporting the efficacy of EPA over other 
polyunsaturated fatty acids is limited, retrospective and observational studies suggest a strong 
correlation between low EPA levels (but not DHA levels) and increased cardiovascular disease 
events. Furthermore, unlike DHA, EPA has not been associated with unintended increases of 
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low-density lipoprotein cholesterol (a CVD risk factor). Evidence from several recent trials 
revealed that EPA therapy, in addition to statins, reduced major cardiovascular events such as 
death, myocardial infarction, or stroke, and decreased various biomarkers and risk factors for 
cardiovascular events without increasing non-cardiovascular mortality. The proposed and 
identified mechanisms by which EPA reduced cardiovascular risk support the prediction of both 
short and long-term cardio-protective benefits and suggest potential benefits and indications 
for other conditions such as dementia and depression (EPA’s use for these latter conditions are 
also being investigated). Additionally, researchers have not defined any significant increase in 
adverse effects when comparing EPA and statin combination therapy with statin monotherapy. 
Accordingly, clinicians may consider prescription EPA for patients, especially for those who have 
significant residual cardiovascular risk despite treatment with a high intensity statin. 
Nonetheless, further research will be necessary to confirm EPA’s long-term safety, its efficacy 
for clinical (rather than surrogate) outcomes, patient acceptance, and potential applications for 
its use in both primary and secondary prevention of cardiovascular disease. Finally, improving 
risk stratification tools may direct (or limit) certain treatments to specific subsets of the 
population and thus optimize utilization of resources.  
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